Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
复制标题
DOI：
10.1136/jitc-2020-001235
复制
发表时间：
2020-12
影响因子：
10.9
通讯作者：
Bishop MR
中科院分区：
文献类型：
--
作者：
Neelapu SS;Adkins S;Ansell SM;Brody J;Cairo MS;Friedberg JW;Kline JP;Levy R;Porter DL;van Besien K;Werner M;Bishop MR
最近开发和临床实施的新型免疫疗法治疗霍奇金淋巴瘤和非霍奇金淋巴瘤，改善了患者的结局。然而，将免疫抑制剂快速引入临床提出了关于现有化疗/放疗方案的最佳治疗方案的重大问题，以及需要更好地理解如何正确管理患者和识别毒性。为了应对这些挑战，癌症免疫治疗学会（SITC）召集了一个淋巴瘤专家小组，为医疗保健专业人员的免疫治疗各个方面的教育制定了临床实践指南。该小组讨论的主题包括治疗计划，免疫相关不良事件（irAE）以及免疫治疗和干细胞移植的整合，以形成指导医疗保健专业人员治疗淋巴瘤患者的建议。
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.
登录
查看更多内容
影响因子：
10.9
作者：
Boyiadzis M;Bishop MR;Abonour R;Anderson KC;Ansell SM;Avigan D;Barbarotta L;Barrett AJ;Van Besien K;Bergsagel PL;Borrello I;Brody J;Brufsky J;Cairo M;Chari A;Cohen A;Cortes J;Forman SJ;Friedberg JW;Fuchs EJ;Gore SD;Jagannath S;Kahl BS;Kline J;Kochenderfer JN;Kwak LW;Levy R;de Lima M;Litzow MR;Mahindra A;Miller J;Munshi NC;Orlowski RZ;Pagel JM;Porter DL;Russell SJ;Schwartz K;Shipp MA;Siegel D;Stone RM;Tallman MS;Timmerman JM;Van Rhee F;Waller EK;Welsh A;Werner M;Wiernik PH;Dhodapkar MV
通讯作者：
Dhodapkar MV
影响因子：
17.1
作者：
Brentjens RJ;Davila ML;Riviere I;Park J;Wang X;Cowell LG;Bartido S;Stefanski J;Taylor C;Olszewska M;Borquez-Ojeda O;Qu J;Wasielewska T;He Q;Bernal Y;Rijo IV;Hedvat C;Kobos R;Curran K;Steinherz P;Jurcic J;Rosenblat T;Maslak P;Frattini M;Sadelain M
通讯作者：
Sadelain M
影响因子：
158.5
作者：
CANELLOS, GP;ANDERSON, JR;PETERSON, BA
通讯作者：
PETERSON, BA
影响因子：
6.2
作者：
Abramson, Jeremy S.;Irwin, Kelly E.;Davis, Benjamin
通讯作者：
Davis, Benjamin
DOI：
10.1200/jco.2017.76.0793
发表时间：
2018-05-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Armand P;Engert A;Younes A;Fanale M;Santoro A;Zinzani PL;Timmerman JM;Collins GP;Ramchandren R;Cohen JB;De Boer JP;Kuruvilla J;Savage KJ;Trneny M;Shipp MA;Kato K;Sumbul A;Farsaci B;Ansell SM
通讯作者：
Ansell SM